Zimmer Biomet (NYSE:ZBH) today increased its 2026 outlook after posting Street-beating second-quarter results.
The company increased its expected revenue growth from a range of 2.5%–4.5% to 3.9%–4.9%. It also increased its expectations for adjusted earnings per share (EPS), going from a range of $8.40–$8.55 to $8.47–$8.59.
Shares of ZBH ticked up nearly 3% to $98.56 apiece in pre-market trading today.
The Warsaw, Indiana–based orthopedic device giant reported profits of $198.3 million. That equals $1.03 per share on sales of $2.18 billion for the three months ended June 30, 2026.
Zimmer Biomet recorded a 29.8% bottom-line gain on a sales increase of 4.8%. The company reported 0.4% growth in its Knee business, 5% growth in Hip and 6.4% growth in Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic (S.E.T.).
Adjusted to exclude one-time items, earnings per share came in at $2.07. That landed 6¢ ahead of expectations on Wall Street. Sales also edged out the forecasts as experts projected $2.14 billion in revenue.
Highlights in the quarter included FDA 510(k) clearance for an advanced version of its Rosa Shoulder System and an agreement to acquire nerve therapy technology from Pacira BioSciences.
“We delivered strong second quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation,” said Ivan Tornos, chair, president and CEO of Zimmer Biomet. “With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted EPS guidance for the year. Importantly, we continue to advance our strategic priorities and remain confident our efforts will strengthen our business, build the boldest leader in MedTech, and better position Zimmer Biomet to deliver consistent, durable growth over the long term.”
